Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(33%)

Phase Distribution

Ph phase_1
2
67%
Ph phase_2
1
33%

Phase Distribution

2

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 2Efficacy & side effects
1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(1)
Terminated(1)
Other(1)

Detailed Status

Suspended1
Completed1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (66.7%)
Phase 21 (33.3%)

Trials by Status

suspended133%
completed133%
terminated133%

Recent Activity

0 active trials
Showing 3 of 3
suspendedphase_2

Evaluation of Safety and Efficacy of IRX4204 in Mild to Moderate Plaque Psoriasis

NCT06723171
terminatedphase_1

Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC

NCT02991651
completedphase_1

Study of IRX4204 for Treatment of Early Parkinson's Disease

NCT02438215

Clinical Trials (3)

Showing 3 of 3 trials
NCT06723171Phase 2

Evaluation of Safety and Efficacy of IRX4204 in Mild to Moderate Plaque Psoriasis

Suspended
NCT02991651Phase 1

Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC

Terminated
NCT02438215Phase 1

Study of IRX4204 for Treatment of Early Parkinson's Disease

Completed

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3